CoChat

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial

Open access
Davidson, Jonathan R.T., Wittchen, Hans-Ulrich, Llorca, Pierre-Michel, Erickson, Janelle, Detke, Michael, Ball, Susan G., Russell, James M. · 2008 · European Neuropsychopharmacology
Cited by 68

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

The objective was to examine duloxetine 60-120 mg/day treatment for relapse prevention in adults with generalized anxiety disorder (GAD). Adult patients (N=887; mean age=43.3 years; 61.0% female) with DSM-IV-TR-defined GAD diagnosis were treated with duloxetine for 26 weeks. Patients who completed open-label phase and were treatment responders (>or=50% reduction in Hamilton Anxiety Rating Scale total score to <or=11 and "much"/"very much improved" ratings for the last 2 visits of open-label phase) were randomly assigned to receive duloxetine or placebo for a 26-week double-blind continuation phase. Relapse was defined as >or=2-point increase in illness severity ratings or by discontinuation due to lack of efficacy. During the double-blind phase, placebo-treated patients (N=201) relapsed more frequently (41.8%) than duloxetine-treated patients (13.7%, N=204, P<or=0.001) and worsened on each outcome measure (P<or=0.001, all comparisons). Duloxetine 60-120 mg/day treatment was efficacious and reduced risk of relapse in patients with GAD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.euroneuro.2008.05.002

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 25

  1. Acharya, 2007, Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder, J. Clin. Psychopharmacol., 26, 587, 10.1097/01.jcp.0000246216.26400.db · DOI · Paper page
  2. Allgulander, 2006, Prevention of relapse in generalized anxiety disorder by escitalopram treatment, Int. J. Neuropsychopharmacol., 9, 495, 10.1017/S1461145705005973 · DOI · Paper page
  3. Allgulander, 2007, Pharmacotherapy for generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of 3 clinical trials, Curr. Med. Res. Opin., 23, 1245, 10.1185/030079907X182202 · DOI · Paper page
  4. Beck, 1979, Assessment of suicidal ideation: the Scale for Suicidal Ideation, J. Consult. Clin. Psychol., 47, 343, 10.1037/0022-006X.47.2.343 · doi:10.1037/0022-006x.47.2.343 · Paper page
  5. Boden, 2007, Anxiety disorders and suicidal behaviors in adolescence and young adulthood: findings from a longitudinal study, Psychol. Med., 37, 431, 10.1017/S0033291706009147 · DOI · Paper page
  6. Endicott, 1993, Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure, Psychopharmacol. Bull., 29, 321
  7. EuroQol Group, 1990, EuroQol: a new facility for the measurement of health-related quality of life, Health Policy, 16, 199, 10.1016/0168-8510(90)90421-9 · DOI · Paper page
  8. Gelenberg, 2000, Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial, JAMA, 283, 3082, 10.1001/jama.283.23.3082 · DOI · Paper page
  9. Goodman, 2004, Selecting pharmacotherapy for generalized anxiety disorder, J. Clin. Psychiatry, 65, 8
  10. Hamilton, 1959, The assessment of anxiety states by rating, Br. J. Med. Psychol., 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  11. Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/YIC.0b013e32807fb1b2 · DOI · Paper page
  12. Keller, 2002, Raising the expectations of long-term treatment strategies in anxiety disorders, Psychopharmacol. Bull., 36, 166
  13. Koponen, 2007, Efficacy of duloxetine for treatment of generalized anxiety disorder: implications for primary care physicians, Prim. Care Companion J. Clin. Psychiat., 9, 100
  14. Lipman, 1976, Outpatient treatment of neurotic depression: medication and group psychotherapy, Proc. Annu. Meet. Am. Psychopathol. Assoc., 64, 178
  15. Mahe, 2000, Long-term pharmacological treatment of generalized anxiety disorder, Int. Clin. Psychopharmacol., 15, 99, 10.1097/00004850-200015020-00006 · DOI · Paper page
  16. McManus, 2004, Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia, Aust. N. Z. J. Psychiatry, 38, 450, 10.1080/j.1440-1614.2004.01383.x · DOI
  17. Raskin, 1969, Replication of factors of psychopathology in interview, ward behavior and self-report ratings of hospitalized depressives, J. Nerv. Ment. Dis., 148, 87, 10.1097/00005053-196901000-00010 · DOI · Paper page
  18. Rynn, 2008, Efficacy and safety of duloxetine in treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial, Depress. Anxiety, 25, 182, 10.1002/da.20271 · DOI · Paper page
  19. Sheehan, 1998, The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10, J. Clin. Psychiatry, 59, 22
  20. Sokero, 2003, Suicidal ideation and attempts among psychiatric patients with major depressive disorder, J. Clin. Psychiatry, 64, 1094, 10.4088/JCP.v64n0916 · DOI · Paper page
  21. Stein, 2006, Antidepressant adherence and medical resource use among managed care patients with anxiety disorders, Psychiatric Serv., 57, 673, 10.1176/ps.2006.57.5.673 · doi:10.1176/ps.2006.57.5.673 · Paper page
  22. Stocchi, 2003, Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder, J. Clin. Psychiatry, 64, 250, 10.4088/JCP.v64n0305 · DOI · Paper page
  23. Thase, 2005, Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, J. Clin. Psychopharmacol., 25, 132, 10.1097/01.jcp.0000155815.44338.95 · DOI · Paper page
  24. Wittchen, 2001, Generalized anxiety disorder: nature and course, J. Clin. Psychiatry, 62, 15
  25. Zigmond, 1983, The Hospital Anxiety and Depression Scale, Acta Psychiatr. Scand., 67, 361, 10.1111/j.1600-0447.1983.tb09716.x · DOI · Paper page

Cited by

See all 68

Metadata

Authors
Davidson, J. R. T., Wittchen, H.-U., Llorca, P.-M., Erickson, J., Detke, M., Ball, S. G., & Russell, J. M.
Venue
European Neuropsychopharmacology
Publisher
Elsevier BV
Published
2008-09
Volume
18
Issue
9
Pages
673-681
ISSN
0924-977X (ISSN-L)
OpenAlex
W2010388663
Cited by
68
References
8
FWCI
11.29
Type
journal article
Language
en
Open access
green
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. https://app.cochat.ai/papers/10.1016/j.euroneuro.2008.05.002
The paper
Davidson, J. R. T., Wittchen, H.-U., Llorca, P.-M., Erickson, J., Detke, M., Ball, S. G., & Russell, J. M. (2008). Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: A double-blind placebo-controlled trial. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2008.05.002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.